Список литературы:

1. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр) Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов, Москва.

2. Балуда В.П., Балуда М.В., Тлепшуков И.К. Физиология системы гемостаза.

М., 1995;

3. Баркаган З.С. и соавт. Клинико-патогенетические варианты, номенклатура и основы диагностики гематогенных тромбофилий. Пробл. гематол. 1996; 3: 5-15. www.hemostas.ru/public/p10.htm;

4. Боброва Л.А., Козловская Н.Л., Шкарупо В.В. и соавт. Влияние генетической формы тромбофилии на клинико-морфологические проявления и характер течения хронического гломерулонефрита. Нефрология и диализ 2010; т.12, №1; С. 25-33;

5. Винников, А. В., Мамась А. Н. Системная гемодинамика у беременных с гестозом при использовании различных видов анестезии// Актуальные проблемы медицины – Гродно.–2009. – с. 132–134;

6. Габриелян, И. И. Скрининговый метод определения средних молекул в биологических жидкостях: метод. рекоменд. – Москва.– 1985. – с. 20;

7. Гурьева В.А., Момот А.П., Сердюк Г.В., Хореев Н.К.. Методические рекомендации по профилактике тромбоза глубоких вен и ТЭЛА у беременных. 2007 г, Барнаул;

8. Зозуля О.В., Сидорова И.С., Макаров И.О. и соавт. Почечная и маточная гемодинаика у беременных с хроническим гломерулонефритом гипертонического типа. Терапевтический архив, 2002.-N 10.-С.52-55;

9. Калашникова Л.А. Сосудистое поражение головного мозга у больных с livedo reticularis Клиническая медицина 1986; 9: 48-53;

10 .Кирсанова Т.В., Козловская Н.Л., Кушнир В.В. и соавт. Ультразвуковая допплерография почечных сосудов в диагностике поражения почек при тромботических микроангиопатиях. Нефрология и диализ 2008; т. 10, №3- 4;

11 .Кирсанова Т.В., Козловская Н.Л., Калашникова Л.А. и соавт. Особенности поражения почек у больного с синдромом Снеддона.

12 .Козловская Н. Л., Боброва Л. А. Генетическая тромбофилия и почки.

Клиническая нефрология. - 2009.-3. - С. 23-34;

13 .Козловская Н.Л., Кирсанова Т.В., Калашникова Л.А. и соавт. Поражение почек при синдроме Снеддона. Нефрология и диализ, 2011; т. 13, №4;

14 .Козловская Н.Л., Макаров И.О., Рогов В.А. и соавт. Хронический гломерулонефрит и беременность. Терапевтический архив, 2004.-N 9.- С.21-26;

15. Козловская Н.Л., Сидорова И.С., Рогов В.А. и соавт. Состояние эндотелия и тромбоцитов у беременных с хроническим гломерулонефритом и лечебные возможности ацетилсалициловой кислоты и дипиридамола. Терапевтический архив, 2004.-N 12.-С.58-64;

16 .Козловская Н.Л., Шахнова Е.А., Кушнир В.В. и соавт. Длительное применение прямых и непрямых антикоагулянтов для лечения нефропатии, ассоциированной с антифосфолипидным синдромом (АФСН). Нефрология и диализ 2005; т. 7, №3;

17 .Козловская Н.Л., Шилов Е.М., Метелева Н.А и соавт. Клинико- морфологические особенности нефропатии при первичном и вторичном антифосфолипидном синдроме. Тер.архив 2007; № 6: 16-25;

18 .Крылова М.Ю. Тромбоцитарные нарушения у больных хроническим гломерулонефритом во время беременности. Автореф. дисс. канд. мед. наук - М,1997;

19 .Макацария А.Д., Бицадзе В.О., Гениевская М.Г. и др.

Антифосфолипидный синдром в акушерской практике. М.Руссо; 2000;

20 .Макацария А.Д., Бицадзе В.О. Тромбофилии и противотромботическая терапия в акушерской практике. – М.: Триада-Х, 2003;

21 .Макацария А.Д., Бицадзе В.О, Акиньшина С.В.. Тромбозы и тромбоэмболии в акушерско-гинекологической клинике.–М.:ООО

«Медицинское информационное агенство», 2007.- С.1047-1054;

22 .Макацария А.Д., Бицадзе В.О Антифосфолипидный синдром, генетические тромбофилии в патогенезе основных форм акушерской патологии. Русский медицинский журнал. Спец.выпуск 2006: 2-10;

23 .Ольхова Е.Б. Эхографическая оценка почек при рефлюкс-нефропатии у детей. Детская хирургия1999;5:27-31;

24 .Пчелкина И.Б., Момот А.П.

25 .Савельева Г.М. с соавт. Эклампсия в современном акушерстве.

Aкушерство и гинекология, 2010, №6, с. 4-9;

26.Cандриков В.А., Садовников В.И. Клиническая физиология трансплантированной почки. М.: МАИК "Наука/Интерпериодика", 2001: 14;

27 .Сухих Г.Т., Мурашко Л.Е. Преэклампсия – М.:ГЭОТАР-Медиа, 2010.- 566с;

28 .Тареева И.Е. Нефрология: Руководство для врачей.-М.:Медицина,2000. – С.464-473;

29 .Шилов Е.М., Козловская Н.Л., Метелева Н.А. и соавт. Клинические проявления нефропатии, связанной с антифосфолипидным

синдромом, при первичном антифосфолипидном синдроме. Терапевтический архив. 2003; 75 (6): 22—7;

30 .Шифман Е.М..- Преэклампсия. Эклампсия. HELLP-синдром.

Петрозаводск: «ИнтелТек», 2002. – 6-11с;

32. British Committee for Standards in Haematology. Guidelines on the investigation and management of thrombophilia. J Clin Pathol 1990; 43: 703- 709;

33. GAIN. Management of Severe Pre-eclampsia and Eclampsia. Guidelines and Audit Implementation Network; 2012 March;

34. National Kidney Foundation. Kidney Disease Outcome Quality Initiative (KDOQI). Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease // Am. J. Kidney Dis., 2007. — Vol. 49 (suppl. 2). — P. S1-S180;

35. RCOG. Guideline No. 10(A). The Management of Severe Pre- eclampsia/Eclampsia 2010;

36. World Health Organization. Inherited Thrombophilia: Report of a Joint WHO/International Society of Thrombosis and Haemostasis (ISTH) Meeting. Geneva, Switzerland: World Health Organization; November 6–8, 1995;

37.

38. Aita K, Etoh M, Hamada H. et al. Acute and transient podocyte loss and proteinuria in preeclamsia // Nephron Clin Practice. 2009. Vol. 112. Р. 65-70;

39. Ballermann BJ. Glomerular endothelial cell differentiation. Kidney Int.2005.

Vol.67. P.1668-1671;

40. Ballegeer V., Mombaerts P., Declerck P. J. et al. Fibrinolytic response to venous occlusion and fi brin fragment D-dimer levels in normal and complicated pregnancy // Thromb. Haemost. - 1987. - Vol. 58, № 4. - P. 1030-1032;

41. Bar J. et al. Microalbuminuria after pregnancy complicated by preeclampsia.

Nephrol Dial Transplant 1999; 14: 1129-1132;

42. Bates S.M., Greer I.A., Sofaer S.,Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American college of Chest physicians. Evidence-based clinical practice guidelines (8th edition). Chest 2008;133;844-886;

43. Baumwell A, Karumanchi SA. Pre-eclampsia: clinical manifestation and molecular mechanisms // Nephron Clin Pract. 2007. Vol.106. P. 72-81;

44. Bolle G, Patey N, Cazajous G et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib // Nephrol Dial Transplant. 2009. Vol.24. P. 682-685;

45. Branch DW, Silver RM, Blackwell JL et al. Outcome of treated pregnancies in women with antiphospolipid syndrome: an update of the Utach experience. Obstet Gynecol 1992;80:614-620;

46. Brown MA, Lindheimer MD, de Swiet M et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). (Review) // Hypertens pregnancy. 2001 Vol. 20(1). P. 9-14;

47. Chandiramani M, Shennan A: Hypertensive disorders of pregnancy: a UK-based perspective. Curr Opin Obstet Gynecol 2008; 20: 96–101;

48. Chappal LC, Enye St. Seed P, Briley AL, Poston L, Shennan AH: Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study.

49. Cohen AW, Burton NG. Nephrotic syndrome due to preeclamptic nephropathy in hydatidiform mole and coexistent fetus // Obstet Gynaecol. 1979. Vol. 53. P. 130-13;

50. Davison J.M., Dunlop W.: Renal hemodynamics and tubular function normal human pregnancy. Kidney Int 18:152-161, 1980;

51. Dekker GA, de Vries JIP, Doelitzsch PMet al. Underlying disorders associated with severe early-onset preeclampsia // Am J Obstet Gynecol. 1995. Vol. 173. P. 1042–1048;

52. Duley L., Gulmezoglu J., Henderson-Smart D.J. Magnesium sulphate and other anticonvulsants for women with preeclampsia (Cochrane Review) // The Reproductive Health Library, Issue 10. – 2007;

53. Eremina V, Jefferson A, Kowalewska J et al, VEGF inhibition and renal thrombotic microangiopathy // N Engl J Med. 2008. Vol. 358. P.1129-1139;

54. Eremina V., Sood M., Haigh J. et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases J. Clin. Invest. 2003; 111 (5): 707—16;

55. Fisher K.A., Ahuja S., Luger A.M. et al. Nephrotic proteinuria with preeclampsia // Am J Obstet Gynecol. 1977. Vol. 129. P. 643-646;

56. Gaber LW, Spargo BH: Pregnancy-induced nephropathy: The significance of focal segmental glomerulosclerosis. Am J Kidney Dis 1987 9: 317–323;

57. Garovic V, Wagner S, Petrovic L. et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia // Nephrol Dial Transplant. 2007. Vol. 22. P. 1136-1143;

58. Garovic VD, Wagner SJ, Turner ST. Urinary podocyte excretion as a marker for preeclampsia // Am J Obst Gynecol. 2007. Vol.196. P.320-327;

59. Goforth RL, Rennke H, Sethi S. Renal vascular sclerosis is associated with inherited thrombophilias. Kidney Int 2006;70: 743-50;

60. Hay J.E. Liver disease in pregnancy // Hepatology. - 2008. - Vol. 47, № 3. - P.

1067-1076;

61. Heaton JM, Turner DR. Persistent renal damage following pre-eclampsia: A renal biopsy study of 13 patients.

62. Henao D, Saleem MA, Cadavid AP. Glomerular disturbances in preeclamsia: disruption between glomerular endothelium and podocyte symbiosis // Hypertens Pregnancy. 2009. Vol.1. P. 1-11;

63. Hertig A., Watnick S., Strevens H. et al. How should women with pre- eclampsia be followed up? New insights from mechanistic studies. Nature Clin. Pract. Nephrol. 2008; 4 (9): 503—9;

64. Hiroaki Onishi, Kimiko Kaniyu, Mitsutoshi Iwashita, et al. Фибрин- мономерные комплексы у здоровых беременных женщин: потенциальный маркер тромбоза при беременности. Ann Clin Biochem 2007; 44: 449–45;

65. Hladunewich M., Karumanchi A., Lafayette R. Pathophysiology of the Clinical Manifestations of Preeclampsia // Clin. J. Am. Soc. Nephrol. - 2007. - Vol. 2. - P. 543-549;

66. Iasmina M. Craici, Steven J. Wagner, Kent R. Bailey at all. Podocyturia Predates Proteinuria and Clinical Features of Preeclampsia. Hypertension. 2013;61:6 1289-1296;

67. Ihle BU, Long P, Oats J. Early onset preeclampsia: Recognition of underlying renal disease // Br Med J (Clin Res Ed) 1987. Vol.294. P.79;

68. Jacob D., Clement D., Bretelle F. et al. Consensus conference. Thrombophilia and pregnancy – Preventing maternal and placental thrombosis. Guidelines (short version) 14 March 2003 - Institut Pasteur – Paris, France. www.has- sante.fr;

69. James PR, Nelson-Piercy C. Management of hypertension before, during and after pregnancy // Heart. 2004. Vol. 90. P. 1499-1504;

70. Karumanchi SA, Lindheimer MD: Advances in Understanding of eclampsia.

Current Hypertension Reports 2008; 10: 305–12;

71. Karumanchi SA, Maynard SE, Stillman IE et al. Preeclampsia: a renal perspective // Kidney Intern. 2005. Vol. 67. P.2101-2113;

72. Kearney J. B., Kappas N. C., Ellerstrom C. et al. The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood 2004; 103(12): 4527 – 4535;

73. Koupepidou P., Deltas C., Christofides T.C. et al. The MHTFR 677TT and 677CT/128AC genotypes in Cypriot patients may be predisposing to hypertensive nephrosclerosis and chronic renal failure. Int Angiol 2005; 24: 287-94;

74. Lafayette R.A., Druzin M., Sibley R., Derby G., Malik T., Huie P. et al. Nature of glomerular dysfunction in pre-eclampsia. Kidney Int. 1998; 54 (4): 1240—9;

65;

75. Leanne Bellamy, Juan-Pablo Casas, Aroon D Hingorani, David J Williams.

BMJ 2007;335:974;

76. Lee RM, Brown MA, Branch DW et al. Anticardiolipin and anti-B2 glycoprotein-I antibodies in preeclampsia // Obstet Gynecol. 2003. Vol. 102. P. 294 –300;

77. Lensen, R.P., Rosendaal, F.R., Koster, T. еt al. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood 1996; 88: 4205-4208;

78. Levine RJ, Maynard SE, Quan C, et al. Circulating angiogenic factors and the risk of preeclampsia // N Engl J Med. 2004. Vol. 350. P. 672-83;

79. Li B, Ogasawara AK, Yang R, et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension. 2002;39(6):1095– 1100

80. Lima F., Khamashta M., Buchanan N.M. et al. A study of sixty pregnancies in patients with antiphospolipid syndrome. Clin Exp Pheumatol.1996; 14:131-136;

81. Magee LA, Helewa M, Moutquin JM, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. Mar 2008;30(3 Suppl):S1-48;

82. Marumoto Y., Kaibara M., Murata T. Hemorheological studies on platelet counts and size in normal pregnancy and pregnancies with preeclampsia and intrauterine growth retardation // Acta. Obstet. Gynaecol. Jap. - 1989. - Vol. 41,

№ 9. - P. 1380-1381;

83. Maynard SE, Min JY, Lim KH et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelian dysfunction, hypertension, and proteinuria in preeclampsia // J Clin Invest. 2003. Vol. 111. P. 649-658;

84. Mello G., Parretti E., Marozio L., et al. Thrombophilia Is Significantly Associated With Severe Preeclampsia: Results of a Large-Scale, Case- Controlled Study. Hypertension 2005;46;1270-1274;

85. Michael P. Metz. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate // The Medical Journal of Australia MJA, 2006. — 184 (1). — Р. 41;

86. Mith М.С., Moran Р., Ward M.K., Davison J.M. Assessment of glomerular filtration rate during pregnancy using the MDRD formula // BJOG: An International Journal of Obstetrics & Gynaecology. — January 2008. — Vol. 115. — № 1. — Р. 109-112;

87. Moe S., Drueke T., Cunningham J. et al. Defi nition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) // Kidney Int., 2005. — Vol. 67. — P. 2089—2100;

88. Moran P., Baylis P.H., Lindheimer M.D.: Glomerular ultrafiltration in normal and preeclamptic pregnancy. J Am Soc Nephrol 14:648-652,2003;

89. Muller-Deile J, Worthman K, Saleem I et al. The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am J Physiol – Renal Physiol. 2009. Vol. 297. P. 1656-1667;

90. Muller-Deile J, Schiffer M. Renal involvement in preeclampsia: similarities to VEGF ablation therapy // J of Pregnancy. 2011. Vol. 2011. 6 pages. Article ID 176973;

91. Murakami S., Saitih M., Kubo T. et al. Renal desease in woman with severe preeclampsia or gestational proteinuria. Obstet Gynaecol 2000; 96:945-949;

92. Nakagawa T., Lan H. Y., Zhu H. J. et al. Differential regulation of VEGF by TGF-beta and hypoxia in rat proximal tubular cells. Am J Physiol Renal Physiol 2004; 287(4): Р.658 – 664;

93. Nisell H., Lintu H., Lunell N.O. et al. Blood pressure and renal function sevev years after pregnancy complicated by hypertension. Br J Obstet Gynaecol 1995; 102:876-881;

94. Noris M, Perico N, Remuzzi G. Mechanisms of disease: pre-eclampsia // Nature Clin Pract Nephrol. 2005. Vol. 1(2). P. 98-114;

95. Okuda Y, Tsurumaru K, Suzuki S, et al. Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sciences. 1998;63(6):477–484;

96. Patel T.V., Morgan G.A., Demetri G.D. et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria indused by the multitargeted kinase inhibitors sunitinib and soferenib. Journal of the National Cancer Institute. 2008; 100-4:282-284;

97. Poon LCY, Kametas NA, Maiz N et al. First – trimestre prediction of hypertensive disorders in pregnancy // Hypertension. 2009. Vol. 53. P. 812-818;

98. Powe C.E., Levine R.J., Karumanchi S.A. Preeclampsia, a disease of the maternal endothelium. The role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011; 123: 2856—69;

99. Quaggin SE, Coffman TM. Toward a mouse model of diabetic nephropathy: is endothelial nitric oxide synthase the missing link? Journal of the American Society of Nephrology. 2007;18(2):364–366;

100. Raife T.J., Lentz S.R., Atkinson B.S. et al. Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood 2002; 99: 437-442;

101. Reiter L., Brown M.A., Whitworth J.A. Hypertension in pregnancy: the incidence of underlying renal disease and essential hypertension. Am J Kidney Dis 1994;24:883-887;

102. Robinson E., Matulonis U., Ivy P. et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial grown factor receptor inhibitor. 2010 Clinical Journal of the American Society of Nephrology, vol.5-3.pp.477-483;

103. Rodie V., Freeman D.J., Sattar N. Et al. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy. Atherosclerosis. – 2004.-Vol.175, N 2.-P.189-202;

104. Roubey RAS Mechanisms of autoantibody-mediated thrombosis. Lupus 1998; 7: S114-S119;

105. Saudan P., Brown M.A., Buddle M.L., Jones M. Does gestational hypertension become pre-eclampsia? Br. J. Obstet. Gynecol. 1998; 105 (11): 1177—84;

106. Scaffer N, Dill L., Cadden J.: Uric acid clearance in normal pregnancy and preeclampsia. J Clin Invest. 1943.- 22:201-206;

107. Sibai BM. Evaluation and management of severe preeclampsia before 34 weeks' gestation. American journal of obstetrics and gynecology. Sep 2011;205(3):191-198; 82;

108. Simon M, Grone H-J, Johren O. et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995; 37 : Р.24-250;

109. Sneddon I.B. Cerebro-vascular lesions and livedo reticularis. Br. J. Dermatol 1965; 77 (April 1): 180-185;

110. Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia // J Am Soc Nephrol. 2007. Vol. 18. P. 2281-2284;

111. Strevens H, Wide-Swensson D, Hansen A. еt al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia // Br J Obst Gynecol. 2003. Vol. 110. P. 831-836;

112. Sucker C., Farokhzad F., Kurschat C. et al. The Homozygous Leu Variant of the Factor XIII Val34Leu Polymorphism as a Risk Factor for the мanifestation of thrombotic microangiopathies. Clin Appl Thromb Hemost 2009; 15; 197-200;

113. Sucker C., Hetzel G.R., Farokhzad F., et al. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies-- a pilot study. Nephrol Dial Transplant. 2007; 22(5):1347-1350;

114. Sucker C., Kurschat C. Farokhzad F. et al. The TT genotype of the polymorphism in the methylentetrahydrofolate reductase as a risk factor in thrombotic microangiopathies: resalt from a pilot study. Clin Appl Thromb Hemost 2009; 15: 283-288;

115. Suga S, Kim Y, Joly A. et al. Vascular endothelial grown factor (VEGF121) protects rats from renal infarction in thrombotic mycroangiopathy. Kidney International, Vol.60 (2001), pp.1297-1308;

116. Sugimoto H, Hamanog Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. Journal of Biological Chemistry. 2003;278(15):12605–12608;

117. Tuffnell D.J., Shennan A. H., Waugh J. S. S. et al. The management of severe preeclampsia / eclampsia // RCOG Guideline. - 2006. - Vol. 10. – Abstract;

118. Van Pampus M.G., Dekker G.A., Wolf H. et al High prevalence of hemostatic abnormalities in women with history of severe preeclampsia. Am. J. Obstet. Gyn. 1999; 180(5);

119. Vikse В., Lorentz M. Irgens et al. Preeclampsia and the Risk of End-Stage Renal Diseasе. Engl. J. Med., 2008; 359: 800 – 809;

120. Yang JC, et al. A randomized double-blind placebo controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer: ASCO meeting abstract. Proc. Am. Soc. Clin. Oncol. 2002;21:A15. Abstract;

121. Yang R, Ogasawara AK, Zioncheck TF, et al. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension. 2002;39(3):815–820;

122. Zhihe Li, Ying Zhang, Jing Ying Ma et al. Recombinant Vascular Endothelial Growth Factor 121 Attenuates Hypertension and Improves Kidney Damage in a Rat Model of Preeclampsia.